SMS Pharmaceuticals announced that Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva.
The company added, "This significant milestone enhances our global regulatory standing and enables the company to increase its presence in the global market for Anti-Retroviral (ARV) APIs."
Commenting on this achievement, P. Vamsi Krishna, Executive Director, stated: The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness."
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
